Table 1. Individualized therapy modifications predicted to prevent tumor progression.

Patient No.	Dose increase factor	Administration interval (days)
3	2.5	15
5	2.3	17
7	3.2	16
12	2.7	16
14	1.5	21
18	2.1	18
20	27.9	1
21	5.0	12
22	5.08	12

Minimal dose increase or maximal administration interval required to prevent in-treatment PSA elevation of more than 10 percent, analyzed for patients who completed the treatment course.